Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and bevacizumab with anti-CD40 CDX-1140 may decrease symptoms, prolonged survival, and improve quality of life in patients with ovarian cancer.
Full description
PRIMARY OBJECTIVES:
I. Determine the safety of anti-CD40 agonist monoclonal antibody CDX-1140 (CDX-1140) combined with pembrolizumab and bevacizumab in patients with recurrent ovarian cancer (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0).
II. Determine the objective response rate (ORR) per immune related response criteria (immune-modified Response Evaluation Criteria in Solid Tumors [iRECIST]).
SECONDARY OBJECTIVES:
I. Determine progression free survival (PFS), disease control rate (DCR) and overall survival (OS).
II. Changes in quality of life measures during the clinical trial (European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30], EORTC QLQ-Ovarian Cancer Module [OV28] and Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)].
EXPLORATORY OBJECTIVES:
I. Pharmacokinetic (PK)/anti-drug antibody (ADA) analysis for CDX-1140. II. Evaluate the immunologic and phenotypic changes in blood samples. III. To obtain data on changes in tumor microenvironment prior to and subsequent to therapy and, to screen for potential biomarkers to predict clinical benefit.
IV. Microbiome analysis from stool, tumor tissue.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive pembrolizumab intravenously (IV) over 30 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity.
ARM II: Patients receive pembrolizumab IV over 30 minutes, bevacizumab IV over 30-90 minutes, and CDX-1140 IV over 90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 6 months for 2 years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Non-absorbed intraarticular corticosteroid and replacement steroids (=< 10 mg/day prednisone or equivalent) will be permitted.
Investigational vaccines (i.e., those not licensed or approved for Emergency Use) are not allowed.
Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
Subject requires or is likely to require more than a two-week course of corticosteroids for intercurrent illness. Subject must complete the course of corticosteroids 2 weeks before screening to meet eligibility.
Subject has a serious, non-healing wound, ulcer, or bone fracture.
Subject has a clinically significant cardiovascular disease including:
Subject has organ allografts.
Subject has clinical symptoms or signs of partial or complete gastrointestinal obstruction or require parenteral hydration and/or nutrition.
Pregnant or nursing female participants.
Known active alcohol or drug abuse.
Unwilling or unable to follow protocol requirements.
Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug.
Primary purpose
Allocation
Interventional model
Masking
80 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal